Compare MHK & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHK | CORT |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 9.7B |
| IPO Year | 1995 | 2001 |
| Metric | MHK | CORT |
|---|---|---|
| Price | $139.48 | $114.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $126.10 | $96.50 |
| AVG Volume (30 Days) | 954.7K | ★ 1.2M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.11 | 0.09 |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | $3.38 | $26.08 |
| Revenue Next Year | $3.09 | $26.98 |
| P/E Ratio | ★ $27.21 | $1,228.89 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $92.99 | $28.66 |
| 52 Week High | $143.13 | $122.21 |
| Indicator | MHK | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 72.02 | 64.64 |
| Support Level | $104.87 | $76.41 |
| Resistance Level | N/A | $122.21 |
| Average True Range (ATR) | 4.01 | 5.13 |
| MACD | 1.21 | -0.09 |
| Stochastic Oscillator | 96.49 | 75.23 |
Mohawk Industries Inc manufactures a wide range of flooring products, including carpets, rugs, ceramic tile, laminate, wood, luxury vinyl tile, and vinyl flooring. Its operating segments include Global Ceramic, Flooring North America, and Flooring Rest of the World. The company generates maximum revenue from the Global Ceramic segment. Global Ceramic designs, manufactures, sources, distributes and markets a broad line of ceramic, porcelain and natural stone tile products used for floor and wall applications in residential and commercial channels for both remodeling and new construction. Geographically, it derives a majority of its revenue from the United States, while it also operates in Latin America, Europe and Others.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.